Marie Terroir

Dr. Marie Terroir

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SLSophie Leboulleux
Sophie Leboulleux
CCChristine Do Cao
Christine Do Cao
SZSlimane Zerdoud
Slimane Zerdoud
MAMarie Attard
Marie Attard
CBClaire Bournaud
Claire Bournaud
IBIsabelle Borget
Isabelle Borget
Purpose: To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.V600E mutation. Patients and Methods: A prospective phase II trial including patients with RECIST progression within 18 months and no lesion > 3 cm. Following a baseline recombinant human (rh)TSH-stimulated diagnostic whole-body scan (dc1-WBS), dabrafenib and trametinib were given for 42 days. A second rhTSH-stimulated dc WBS (dc2-WBS) was done at day 28 and 131I (5.5 GBq–150 mCi after rhTSH) was administered at day 35. Primary endpoint was the 6-month RECIST objective response rate. In case of partial response (PR) at 6 or 12 months, a second treatment course could be given. Among 24 enrolled patients, 21 were evaluable at 6 months. Results: Abnormal 131I uptake was present on 5%, 65%, and 95% of the dc1-WBS, dc2-WBS, and post-therapy scans, respectively. At 6 months, PR was achieved in 38%, stable disease in 52%, and progressive disease (PD) in 10%. Ten patients received a second treatment course: one complete response and 6 PRs were observed at 6 months. The median progression-free survival (PFS) was not reached. The 12- and 24-month PFS were 82% and 68%, respectively. One death due to PD occurred at 24 months. Adverse events (AE) occurred in 96% of the patients, with 10 grade 3–4 AEs in 7 patients. Conclusions: Dabrafenib-trametinib is effective in BRAF p.V600E-mutated DTC patients for restoring 131I uptake with PR observed 6 months after 131I administration in 38% of the patients.


1 July 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
LLL Lamartina
L Lamartina
SIS Ippolito
S Ippolito
MDM Danis
M Danis
FBF Bidault
F Bidault
IBIsabelle Borget
Isabelle Borget
SLS Leboulleux
S Leboulleux
Background: Anti-angiogenic Tyrosine Kinase Inhibitors (TKI) are the mainstay of advanced thyroid cancer (TC) treatment. Concern is rising about TKI-related toxicity. Objective: to determine the incidence and to investigate the risk factors of hemoptysis in TC patients during TKI treatment. Methods: We analyzed consecutive TC patients treated with TKI in our center between 2005 and 2013 and performed an independent review of CT-scan images for airway invasion assessment. Occurrence of grade 1–2 or grade 3–5 hemoptysis according to CTCAE version 4.03 and risk factors for hemoptysis were investigated. Results: 140 patients (89 males, median age: 52 years) with medullary (56%), differentiated (33%) and poorly differentiated TC (11%) were enrolled. Thyroidectomy±neck dissection was performed in 123 patients and neck/mediastinum external-beam radiotherapy (EBRT) in 41 (32% with therapeutic purpose and 68% with adjuvant purpose). Patients received from 1 to 4 lines of TKI (median 1). Median follow-up was 24 months. Airway invasion was found in 65 (46%) cases. Hemoptysis occurred in 9 patients: grade 1–2 in 7 cases (5%) and grade 3–5 in 2 (1.4%) cases (fatal in one). Hemoptysis was associated with presence of airway invasion [p= 0.04], poorly differentiated pathology [0.03], history of therapeutic EBRT [p= 0.003] and thyroidectomy without neck dissection [p= 0.02]. Conclusion: Airway invasion, poorly differentiated pathology, therapeutic EBRT and thyroidectomy without neck dissection are associated with and increased risk of hemoptysis in TC patients during anti-angiogenic TKI treatment. Further research is needed to confirm this data and to sort out interactions between these risk factors. A careful assessment of airway invasion is mandatory before TKI introduction.

6 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DHDana M. Hartl
Dana M. Hartl
JGJoanne Guerlain
Joanne Guerlain
IBIngrid Breuskin
Ingrid Breuskin
JHJulien Hadoux
Julien Hadoux
EBEric Baudin
Eric Baudin
SLSophie Leboulleux
Sophie Leboulleux
Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This article will examine the pros and cons of thyroid lobectomy for low to intermediate risk cancers and discuss, in detail, criteria for patient selection and oncological outcomes.

29 October 2016 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MTMarie Terroir
Marie Terroir
IBIsabelle Borget
Isabelle Borget
FBFrançois Bidault
François Bidault
MRMarcel Ricard
Marcel Ricard
FDFrédéric Deschamps
Frédéric Deschamps
SLSophie Leboulleux
Sophie Leboulleux

1 October 2019 in European Journal of Radiology
Verified
Journal Article
Closed access
MBMaxime Barat
Maxime Barat
LTLambros Tselikas
Lambros Tselikas
Thierry De BaereThierry De Baere
Thierry De Baere
GGG. Gravel
G. Gravel
SYS. Yevich
S. Yevich
FDFrederic Deschamps
Frederic Deschamps